Akademik Veri Yönetim Sistemi
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, cilt.25, sa.9, 2024 (SCI-Expanded, Scopus)
Increased expression and nuclear translocation of beta-CATENIN is frequently observed in breast cancer, and it correlates with poor prognosis. Current treatment strategies targeting beta-CATENIN are not as efficient as desired. Therefore, detailed understanding of beta-CATENIN regulation is crucial. Bone morphogenetic proteins (BMP) and Wingless/Integrated (WNT) pathway crosstalk is well-studied for many cancer types including colorectal cancer, whereas it is still poorly understood for breast cancer. Analysis of breast cancer patient data revealed that BMP2 and BMP6 were significantly downregulated in tumors. Since mutation frequency in genes enhancing beta-CATENIN protein stability is relatively low in breast cancer, we aimed to investigate whether decreased BMP ligand expression could contribute to a high protein level of beta-CATENIN in breast cancer cells. We demonstrated that downstream of BMP stimulation, SMAD4 is required to reduce beta-CATENIN protein stability through the phosphorylation in MCF7 and T47D cells. Consequently, BMP stimulation reduces beta-CATENIN levels and prevents its nuclear translocation and target gene expression in MCF7 cells. Conversely, BMP stimulation has no effect on beta-CATENIN phosphorylation or stability in MDA-MB-231 and MDA-MB-468 cells. Likewise, SMAD4 modulation does not alter the response of those cells, indicating that SMAD4 alone is insufficient for BMP-induced beta-CATENIN phosphorylation. While our data suggest that considering BMP activity may serve as a prognostic marker for understanding beta-CATENIN accumulation risk, further investigation is needed to elucidate the differential responsiveness of breast cancer cell lines.